AWKN — Awakn Life Sciences Cashflow Statement
0.000.00%
HealthcareSpeculativeMicro Cap
Annual cashflow statement for Awakn Life Sciences, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -1.11 | -16.5 | -9.65 | -3.67 |
| Depreciation | ||||
| Non-Cash Items | 0.488 | 7.17 | 1.17 | 0.093 |
| Discontinued Operations | ||||
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.132 | 0.538 | 0.51 | 1.18 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -0.473 | -8.59 | -7.36 | -2.38 |
| Capital Expenditures | -0.201 | -1.71 | -0.095 | — |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -0.015 | 0.022 | 0 | -0.02 |
| Acquisition of Business | ||||
| Sale of Business | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -0.216 | -1.69 | -0.095 | -0.02 |
| Financing Cash Flow Items | — | — | — | -0.2 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 1.06 | 11.5 | 6.4 | 2.46 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0.366 | 1.26 | -1.07 | 0.041 |